Lpath, Inc. Awarded Two Key U.S. Patents Related to iSONEP and ASONEP Drug Programs

SAN DIEGO, CA--(Marketwire - November 15, 2010) - Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, has been issued two key patents by the U.S. Patent and Trademark Office (USPTO).

The first patent (US 7,829,674) contains claims covering the composition of matter for Lpath's anti-Sphingosine-1-Phosphate (S1P) antibody, sonepcizumab, the active component in Lpath's two lead compounds, iSONEP™ and ASONEP™.

The second patent (US 7,794,713) is a method-of-use patent, with claims covering the use of anti-S1P antibodies for treating S1P-associated hyperproliferative diseases associated with aberrant cardiac remodeling, such as cardiac failure and restenosis.

Lpath was previously awarded a U.S. patent covering uses of anti-S1P antibodies in the treatment of cancer (US 7,169,390).

According to Dr. Laurel Bernstein, executive director of intellectual property for Lpath, "The USPTO has validated the novelty and utility of Lpath's S1P-neutralizing monoclonal antibodies and their use in the treatment of a range of diverse diseases and conditions."

Scott Pancoast, Lpath's CEO, added: "With the issuance of these two patents, our lead programs are further protected, significantly enhancing their commercial value over time."

Lpath recently completed two early-stage clinical trials using sonepcizumab. iSONEP, the ocular formulation of sonepcizumab, was evaluated in a Phase 1 trial in wet-AMD subjects, and ASONEP, the systemic formulation, was evaluated in a Phase 1 trial in cancer subjects. The trials provided strong evidence of an excellent safety profile, both systemically and in the eye, and provided insights into their efficacy and pharmacodynamics that will inform Lpath in the design of follow-on studies.

About Lpath's Patent Portfolio
Over the course of the company's development, Lpath has achieved a broad and deep intellectual-property position in the bioactive-lipid area. The company's comprehensive patent portfolio now includes 18 issued patents (including three international), with 105 patent applications (including 70 international). These patents primarily concern the use of reagents and methods designed to interfere with the actions of bioactive lipids involved in human disease.

Lpath's intellectual-property portfolio includes compositions of matter that specifically bind to sphingolipids and sphingolipid metabolites. These agents, including antibodies, could be used in the diagnosis and treatment of various diseases and disorders, including cardiovascular/cerebrovascular disease, cancer, inflammation, autoimmune disorders, ocular disease and angiogenesis.

Lpath has also obtained issued claims on sphingolipid targets (e.g., receptors and signaling sphingolipids) and methods for using such targets in drug-discovery screening efforts.

The company believes that its patent estate provides broad, commercially significant coverage of antibodies, receptors, enzymes, or other moieties that bind to a lysolipid (or a sphingolipid metabolite) for diagnostic, therapeutic, or screening purposes.

About Lpath
San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, two of which -- ASONEP™ for cancer and iSONEP™ for wet AMD -- have completed Phase 1 clinical trials. For more information, visit www.Lpath.com.

About Forward-Looking Statements
The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the results of any future clinical trials for its product candidates and the Company's ability to secure the funds necessary to support its clinical trial and product development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.